DIRS.INFO The most relevant business & tech news

☆ We're overhauling our Bullpen watchlist — 3 stocks are gone, the rest stick around
▼ + stars: | 2024-11-15 | by ( Paulina Likos | ) www.cnbc.com time to read: +4 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. A view of the New York Stock Exchange (NYSE) on Wall Street November 13, 2024, in New York City.

Persons: Jim Cramer, Jim, Brian Chesky, Trump, Marvell, Jim chalked, Matt Murphy's, we're, hasn't, Amgen's, it's, Jim Cramer's, Angela Weiss Organizations: Pepsico, RTX, Marvell Technology, Nvidia, AMD, Broadcom, Novartis, JPMorgan Healthcare, Dow Inc, Jim Cramer's Charitable, CNBC, New York Stock Exchange, AFP, Getty Locations: RTX, Russia, Ukraine, Swiss, China, New York City

☆ GEHC stock finally gets some respect after earnings. Those betting against it got slammed
▼ + stars: | 2024-02-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +8 min

Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. The quarterly earnings result from GE Healthcare on Tuesday is the best of both worlds. Quarterly commentary In addition to the mid-single-digit organic revenue growth, total company orders increased by 3%. The continued divergence in orders between the two companies suggests GE HealthCare is taking market share in the industry. A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

Persons: Eli Lilly, GEHC, It's, Jim Cramer, Philips, we're, GEHC's, We're, Jim Cramer's, Jim Organizations: GE Healthcare Technologies, The, Starbucks, GE Healthcare, General Electric, GE HealthCare, Management, JPMorgan Healthcare, Federal Reserve, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: China, ultrasounds, MRIs, New York

We're selling 95 shares of GE Healthcare at roughly $74. Following Wednesday's trade, Jim Cramer's Charitable Trust will own 1,150 shares of GEHC, reducing its weighting to 2.75% from 2.97%. If hospitals have more of a wherewithal to invest in medical equipment, some of that will go to GE Healthcare. Philips orders have been down for six quarters in a row, but GE Healthcare hasn't seen that weakness yet. With Wednesday's sale, we'll realize a small loss of about 7% on GEHC stock purchased last May.

Persons: Jim Cramer's, GEHC, We've, Jim Cramer, Jim Organizations: GE Healthcare, JPMorgan Healthcare, Philips, GE, JPMorgan, GE Healthcare hasn't, CNBC Locations: China, GEHC

☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
▼ + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.

Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid

☆ Jim Cramer says it's 'totally the wrong time to sell' this life sciences stock on a roll
▼ + stars: | 2024-01-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch audio feature in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Estee Lauder, It's, LVMH, Jefferies, Peltz, Abbott, ABT, Morgan Stanley, Wynn, Brown Forman, Sartorius, Jim, Jim Cramer's Organizations: CNBC, Meta, Disney, DuPont, Constellation Brands, JPMorgan, Jim Cramer's Charitable Locations: German

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ Here's what I'm watching to see where the market goes next after the S&P 500 record close
▼ + stars: | 2024-01-21 | by ( Jim Cramer | ) www.cnbc.com time to read: +10 min

We don't know what we want. The rails are too significant to ignore even as the bond market seems to rely, I would say, wrongly, on the broader data. I think it's a factor of big money flows that aren't sensitive to what moves rates and don't mind being wrong. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Tesla, ServiceNow, Bill McDermott, Russell, —, Abbott, Gamble, Jon Moeller, Heels, what's, hasn't, Steve Jobs, Ray, Kimberly, Clark, Jim Cramer's, Jim Cramer, Jim, Virginia Sherwood Organizations: Union Pacific, CSX, Norfolk Southern, Federal Reserve, Silicon Valley Bank, Microsoft, Nvidia tacking, Google, Apple, Nvidia, JPMorgan Healthcare Conference, Abbott Laboratories, Investing, JPMorgan, Novartis, Walgreens Boots Alliance, Procter, Super, YouTube, Netflix, Vision, Pro, Jim Cramer's Charitable, CNBC, NYSE Locations: U.S, Silicon, San Francisco, Amgen, China

☆ Why we like health-care stocks in 2024 despite their spotty record in presidential election years
▼ + stars: | 2024-01-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

The S & P 500 Health Care Sector index has outperformed the broader S & P 500 in just three of the past eight presidential election years dating back to 1992, according to FactSet data. So far in 2024, health care has been the best-performing sector in the S & P 500, climbing roughly 2%. .GSPHC .SPX YTD mountain Health care sector vs. S & P 500 YTD It's way too early for any grand predictions with Election Day 2024 about 10 months away. Nevertheless, we see attractive fundamentals in the year ahead for a host of health-care stocks, giving us the confidence to own Lilly, GE Healthcare and Danaher despite what history says about the group in presidential election years. After a strong 2022 for health care in a terrible overall market, investors last year placed a lower emphasis on the defensive characteristics of health care.

Persons: —, that's, Eli Lilly, Lilly, Jim Cramer, Jim, Sen, Bernie Sanders of, Joe Biden, Sanders, would've, Damien Conover, Conover, Biden, Eli Lilly's, Morningstar, Amgen, Morningstar's Conover, Lilly's donanemab, Humana, Bausch, Jim Cramer's, Frederick Florin Organizations: Health, GE Healthcare, Abbott Laboratories, Amgen, Novartis, Walgreens Boots Alliance, JPMorgan Healthcare Conference, Democratic, Morningstar, CNBC, Horizon Therapeutics, Novo Nordisk, Federal Reserve, General Electric, Medicare, Humana, UnitedHealth Group, Investors, AFP, Getty Locations: San Francisco, U.S, Bernie Sanders of Vermont, Canadian, Fegersheim, France

☆ The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
▼ + stars: | 2024-01-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Michael Siluk | UCG | Getty ImagesBoehringer IngelheimBoehringer Ingelheim is developing a weight loss drug with Danish biotech firm Zealand Pharma. Some popular weight loss drugs such as Novo Nordisk's Wegovy only target GLP-1. Terns PharmaceuticalsSmaller drugmakers are developing their own weight loss drugs. Quirk acknowledged that it may be difficult for Terns to set its pill apart from other weight loss drugs. Viking Therapeutics expects to release mid-stage trial data on its weight loss injection in the first half of the year.

Persons: Michael Siluk, Boehringer Ingelheim, Erin Quirk, Quirk, it's, Eli Lilly's, Roger Song Organizations: UCG, Getty, Zealand Pharma, Nordisk's, Drug Administration, JPMorgan Healthcare Conference, Pharmaceuticals, Terns Pharmaceuticals, GLP, Viking Therapeutics, Therapeutics, Jefferies Locations: Viking

☆ Cramer likes this health care stock that has corrected but whose fundamentals are improving
▼ + stars: | 2024-01-16 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch audio feature in time for the last hour of trading on Wall Street. Jim Cramer said is looking for stocks that have fallen after a big run but whose fundamentals are improving, like GE Healthcare . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Christopher Waller, Ruth Porat, Morgan Stanley, Danaher, Estee Lauder, Jim Cramer's, Jim Organizations: CNBC, Fed, Bloomberg, GE Healthcare, Nvidia, Palo, Disney, ESPN, NFL, JPMorgan Healthcare, Bank, DuPont, Bank of America, Jim Cramer's Charitable Locations: Davos, Palo Alto

☆ Struggling insurance upstart Oscar is making a long shot bet on a Trump-era program to fuel growth
▼ + stars: | 2024-01-16 | by ( ) www.businessinsider.com time to read: +6 min

The New York insurance company has struggled to find its footing for years. At the top of the list is this little-known Trump-era policy, which offered employers a new way to give workers health benefits. Oscar has struggled with deep lossesBertolini is the former CEO of the insurance company Aetna. The company raised its health plans' prices and renegotiated contracts with healthcare providers and vendors — including its pharmacy-benefit manager — to lower expenses. In the future, Oscar plans to design specific health plans that cater to those types of customers.

Persons: —, Joshua Kushner, Mario Schlosser, Oscar, it's, Mark Bertolini, It's, Bertolini, Trump, Ari Gottlieb, Elijah Nouvelage, haven't Organizations: Service, Business, New, Morgan Healthcare, Aetna, Reuters, HRAs Locations: New York, ICHRAs

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
▼ + stars: | 2024-01-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. Interest in the drugs will only continue this year, as some analysts expect more dealmaking and advancements in ADCs currently in development. The drugs also have potential to draw huge profits: ADCs could account for $31 billion of the $375 billion worldwide cancer market in 2028, according to estimates from the drug market research firm Evaluate. The market for those drugs in 2023 was estimated to be worth around $9.7 billion, another report from research firm MarketsandMarkets said. Everyone wants to gain exposure to [ADCs] and basically make it a cornerstone of their entire corporate strategy," Hsieh told CNBC.

Persons: FRANCISCO —, Johnson, Andy Hsieh, William Blair, MarketsandMarkets, Hsieh Organizations: FRANCISCO, JPMorgan Healthcare Conference, ADC, Pfizer, Merck, William Blair & Company, CNBC Locations: San Francisco, ADCs, drugmakers, Asia

☆ What's old is new: Our 3 best stocks to start 2024 were also big winners last year
▼ + stars: | 2024-01-12 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

Artificial intelligence chipmaker Nvidia , cybersecurity provider Palo Alto Networks and pharma giant Eli Lilly are the Club's biggest gainers to start 2024. Palo Alto Networks, meanwhile, jumped nearly 112% last year, becoming the first cybersecurity company to reach a $100 billion market capitalization . LLY 3M mountain Eli Lilly 3 months Eli Lilly has been positive in six of the eight trading days in 2024, including Thursday's session . PANW 3M mountain Palo Alto Networks 3 months Shares of Palo Alto Networks began 2024 on a rough note, falling in each of the first four trading days amid a larger seven-session skid that stretched into December. Wednesday's advance came after Morgan Stanley hiked its Palo Alto price target to $375 per share from $304.

Persons: haven't, Eli Lilly, Wall, hasn't, Eli Lilly's, Oppenheimer, Lilly, Morgan Stanley, Jim Cramer's, Jim Cramer, Jim Organizations: Nvidia, Palo Alto Networks, pharma, Club, Palo, Consumer, Semiconductor, Mizuho, Truist, Bank of America, JPMorgan Healthcare Conference, CNBC, New York Stock Exchange, Bloomberg, Getty Locations: Palo Alto, Las Vegas, New York, U.S

☆ People Can't Get Ozempic, New Weight-Loss Drugs Because of Broken Healthcare System
▼ + stars: | 2023-04-13 | by ( ) www.businessinsider.com time to read: +15 min

Wegovy is just one of a wave of revolutionary weight-loss drugs, which also includes the buzzy Ozempic, that represents a watershed moment for obesity treatment. Demand for weight-loss drugs is surgingDoctors and healthcare professionals searched for a healthy, safe, and effective weight-loss solution for years before the drugs, known collectively as GLP-1 agonists, exploded on the scene. If there is one key that could unlock access to expensive weight-loss drugs for Americans, it's Medicare. Expanding coverage for Ozempic and other weight-loss drugs for just a small segment of the population could cost Medicare up to $26.8 billion a year. Patients lose outYears from now, patients may have an easier time getting their hands on weight-loss drugs.

A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection. "The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," he said. He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect. Bayer shares lag'HIGHLY ATTRACTIVE'In the United States, a different set of drug market rule changes are underway, with some of the highest-selling products set to see negotiated price discounts under the Inflation Reduction Act (IRA). Among the biggest drivers was the company's decision to prepare a U.S. launch of its next-generation stroke prevention drug asundexian on its own.

☆ Bayer picks outsider Anderson as CEO after investor pressure
▼ + stars: | 2023-02-08 | by ( ) www.reuters.com time to read: +2 min

News of the CEO change sent the German drugs-to-pesticides giant's shares to their highest level in nearly eight months. Shares in Bayer closed up 6% on the news of the new CEO, reaching the top of Frankfurt's blue-chip index and hitting their highest level since June last year. "Bill Anderson's mission is clear: enable Bayer to realize its full potential and create sustainable value for our shareholders, farmers, patients, consumers, employees, and all stakeholders of the company," Winkeljohann added. Sources told Reuters earlier this week that activist investor Jeff Ubben had contacted fellow investors to drum up support for big changes at Bayer, including the swift replacement of Baumann. Reporting by Patricia Weiss, Kirsti Knolle and Christoph Steitz; Editing by Tom Sims and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.

☆ Alignment Healthcare's CEO shared 3 reasons he thinks the upstart will win in health insurance — and why it won't unravel like Bright Health
▼ + stars: | 2023-02-07 | by ( ) www.businessinsider.com time to read: +5 min

Young health insurers that went public in 2021 have bled money. Some health insurers that went public in 2021 at high valuations have struggled since then. Several young insurers have bled money as they've grown quickly. Bright Health, another Medicare Advantage insurer, came close to insolvency and had to shut down its health plans on the Affordable Care Act marketplace. Growing steadily with a narrow focusBefore the recent market slowdown, growing fast had been a common strategy for newly public health insurers and digital health broadly.

☆ Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.
▼ + stars: | 2023-02-02 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +6 min

Advances in depression treatment have been rare over the past few decades. But treatments for mental-health illnesses, like depression, haven't changed much over the past few decades. Insider put together a roundup of the most promising depression treatments today, both those that have won approval and those that are in the later stages of the research process. Unlike most depression treatments on the market, Auvelity is rapid-acting, which means it offers faster relief for patients. MDD is also known as clinical depression and is defined by persistent depressive symptoms.

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

☆ The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
▼ + stars: | 2023-01-20 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +6 min

But amid some positive news, companies focused on Alzheimer's have said they've received an influx of investor interest. In trials, Leqembi was found to slow the rate of cognitive decline by 27% in Alzheimer's patients over 18 months. Eli Lilly's drug donanemab is expected to have data soon but just faced a setback from the FDAEli Lilly's donanemab is the focus of a late-stage trial. In the first half of this year, Eli Lilly is expected to release data for its Alzheimer's drug donanemab, which is being tested in a late-stage trial. Getty ImagesAduhelm, the first Alzheimer's drug to be approved in 18 years, was OK'd by the FDA in 2021 but has faced controversy.

☆ We're finally learning more about how Dollar General could take on the healthcare industry
▼ + stars: | 2023-01-19 | by ( ) www.businessinsider.com time to read: +3 min

Dollar General unveiled plans in 2021 to become a health destination for people in rural areas. Dollar General said it will evaluate whether to bring the clinics to additional stores. Dollar General just started delivering urgent and preventative care to customers in mobile clinics at three of its stores outside of Nashville. Dollar General is among several large retailers hoping to carve out a bigger piece of the $4.3 trillion healthcare industry. Dollar General's healthcare push so far has been limitedDollar General first said it wanted to expand access to healthcare services in rural communities in July 2021.

☆ EQRx promised to deliver cutting-edge drugs at half the cost of rivals. A cofounder shares why the once buzzy biotech is walking away from that mission
▼ + stars: | 2023-01-19 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

After years of touting the idea of radically lower drug prices, EQRx has walked away from that plan. Cofounder Alexis Borisy said it was due to the FDA not OK'ing drugs based only on Chinese data. EQRx suddenly sounded like a typical biotech company, talking of "market-based pricing" that would "maximize value for shareholders." EQRx's stock is down over 75% since its record-breaking SPACAlexis Borisy, EQRx Chairman, and CEO Melanie Nallicheri. An unclear future for 'radically lower drug prices'EQRx CEO Melanie Nallicheri EQRxIn November, EQRx said it wouldn't pursue radically lower pricing for its first two drug candidates, both cancer therapies.

☆ Former CEO says Biogen 'shot themselves in the foot' by deciding to charge $56,000 for its controversial Alzheimer's drug
▼ + stars: | 2023-01-18 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

Former Biogen CEO George Scangos said the biotech priced its Alzheimer's drug Aduhelm too high. After the FDA approved the controversial treatment in 2021, Biogen set a $56,000 list price. "They shot themselves in the foot with the pricing," Scangos, now CEO of Vir Biotechnology, said. SAN FRANCISCO — The former CEO of Biogen told Insider the Massachusetts biotech priced its controversial Alzheimer's drug, Aduhelm, "way too high." "I think Aduhelm works.

☆ What's next for Goldman following deep cuts and organization overhaul
▼ + stars: | 2023-01-17 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +5 min

On tap we've got stories on JPMorgan's Jamie Dimon fielding questions about the bank's acquisition strategy, another bank plans to make cuts, and fast food options that won't completely crush your diet. On Wednesday the bank conducted a majority of its cuts, reducing its global workforce by about 6.5%. A few days later, on Friday, the bank reported losses of more than $3 billion since 2020 in the unit that houses the bank's consumer lending business. Meanwhile, some of the recently axed Goldman employees have been left in the dark on what's next for them, according to reporting from Hayley and Emmalyse Brownstein. Here are some fast food options that won't completely wreck your diet.

Search resuls for: "Morgan Healthcare"

25 mentions found